Merck Serono S. a.

Ares Trading S.a.

Britannia Pharmaceuticals Limited

Merck Patent Gmbh

Ipsen Pharma S.a.s.

Ethypharm, Inc.

Laboratoires Des Produits Ethiques Ethypharm

Mainelab

Joel Richard

Alessandra Del Rio

Jeremiah Harnett

Nathalie Mondoly

Michael J Dey

Rita Agostinetto

Laurent Bertocchi

Marie-Madeleine Baronnet

Helen Gabriela Baldascini

You-Ping Chan

Tsutomu Arakawa

Fabrizio Samaritani

Gianluca Rinaldi

Gauthier Pouliquen

Frantz Deschamps

Jean-Pierre Benoit

Patrice Romain

Susan Park

Frederic Checot

Roger Kravtzoff

Luisa De Angelis

Evert Nicolaas Lamme

Claire Dulieu

Daniel Leblanc

Enona Gopinath

Frédéric CHÉCOT

A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.

Therapeutical composition containing apomorphine as active ingredient

The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26,000 and 40,000 g/mol, grafted with alpha-tocopherol substituents, the average molar grafting ratio being 4.5-5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time.

IFN-beta compositions, preparation methods and uses thereof

The invention relates to a liquid pharmaceutical composition comprising a pegylated IFN-&#x3b2; (PEG-IFN-&#x3b2;), an excipient, a surfactant and a buffer wherein said excipient is a polyol, wherein said surfactant is a non-ionic surfactant and wherein said buffer is a sodium acetate buffer.

PEG-interferon-beta formulations

The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter.

Solid lipid microcapsules containing growth hormone inner core microparticles

The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.

LH liquid formulations

The invention relates to formulations of TACI-Immunoglobulin fusion proteins.

Formulations for TACI-immunoglobulin fusion proteins

Growing community of inventors

Mere, France

Joel Richard